DCPH Stock Recent News

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.55 per share a year ago.

Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. The INSIGHT study is comparing ripretinib against sunitinib in GIST patients who failed imatinib therapy and have specific KIT mutations, showing promising early results. The company has gained approvals in non-US markets and is also developing vimseltinib for tenosynovial giant cell tumor, with positive phase 1/2 results and an anticipated phase 3 readout in 2023.

Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.

Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a part of a combination therapy.

Deciphera saw revenue rise by 17.4% year over year. The company's only marketed therapy is Qinlock to treat advanced GIST.

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.

After a period of bad news, DCPH has slowly inched back into a positive period. They have a lot of good news and some upcoming catalysts. Current prices make it quite attractive.

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New York, NY. A live webcast of the fireside chat will be available on the “Events and Pre.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Jen Larson - Senior Vice President-Finance and Investor Relations Steve Hoerter - President and Chief Executive Officer Matt Sherman - Chief Medical Officer Dan Martin - Chief Commercial Officer Margarida Duarte - Head of International Tucker Kelly - Chief Financial Officer Conference Call Participants Tyler Van Buren - Cowen Bradley Canino - Stifel Reni Benjamin - JMP Securities Andrew Berens - SVB Securities Operator Good morning, everyone, and welcome to Deciphera Pharmaceuticals First Quarter 2023 Financial Results Conference Call. Later, we will conduct a question-and-answer session.